Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
13.11
+0.14 (1.08%)
May 14, 2026, 11:13 AM EDT - Market open
Pharming Group Revenue
Pharming Group had revenue of $72.45M in the quarter ending March 31, 2026, a decrease of -8.40%. This brings the company's revenue in the last twelve months to $369.45M, up 15.18% year-over-year. In the year 2025, Pharming Group had annual revenue of $376.13M with 26.56% growth.
Revenue (ttm)
$369.45M
Revenue Growth
+15.18%
P/S Ratio
2.54
Revenue / Employee
$907,830
Employees
407
Market Cap
940.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 376.13M | 78.93M | 26.56% |
| Dec 31, 2024 | 297.20M | 51.88M | 21.15% |
| Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
| Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
| Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
| Dec 31, 2020 | 212.17M | 22.79M | 12.03% |
| Dec 31, 2019 | 189.39M | 34.10M | 21.96% |
| Dec 31, 2018 | 155.29M | 47.75M | 44.40% |
| Dec 31, 2017 | 107.54M | 90.83M | 543.88% |
| Dec 31, 2016 | 16.70M | 4.94M | 42.05% |
| Dec 31, 2015 | 11.76M | -13.88M | -54.13% |
| Dec 31, 2014 | 25.63M | 16.22M | 172.36% |
| Dec 31, 2013 | 9.41M | -4.59M | -32.77% |
| Dec 31, 2012 | 14.00M | 10.12M | 260.60% |
| Dec 31, 2011 | 3.88M | 3.12M | 406.76% |
| Dec 31, 2010 | 766.09K | 285.75K | 59.49% |
| Dec 31, 2009 | 480.35K | -445.02K | -48.09% |
| Dec 31, 2008 | 925.37K | -83.21K | -8.25% |
| Dec 31, 2007 | 1.01M | 815.16K | 421.44% |
| Dec 31, 2006 | 193.42K | -285.11K | -59.58% |
| Dec 31, 2005 | 478.53K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 360.78M |
| Phathom Pharmaceuticals | 204.89M |
| Geron | 196.12M |
| Xencor | 97.36M |
| MeiraGTx Holdings | 81.39M |
| Janux Therapeutics | 13.73M |
PHAR News
- 5 days ago - Pharming price target lowered to $40 from $41 at Oppenheimer - TheFly
- 7 days ago - Pharming To Present New Leniolisib Pediatric And CVID Data At CIS 2026 - Nasdaq
- 7 days ago - Pharming Group Reports Lower Q1 Revenue, Highlights Joenja Growth And Regulatory Progress - Nasdaq
- 7 days ago - Pharming Group Earnings Call Transcript: Q1 2026 - Transcripts
- 7 days ago - Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders - GlobeNewsWire
- 7 days ago - Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 - GlobeNewsWire
- 8 days ago - Pharming Group (XAMS:PHARM) Q1 2026: Everything You Need To Know Ahead Of Earnings - GuruFocus
- 21 days ago - Pharming Group to report first quarter 2026 financial results and provide business update on May 7 - GlobeNewsWire